Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Orange)
Rumey Ishizawar
LCCC - Clinical Trials
Clinical or Medical
Observational
Cancer (Bladder, Brain and Other Nervous System, Breast, Colorectal, Cervical, Head and Neck, Kidney, Liver, Lung, Melanoma, Pancreatic, Prostate, Sarcoma (bone and soft tissue), Stomach and Esophageal, Thyroid and Other Gland/Endocrine, Other Cancers, Leukemia, Phase 1 Trials (all cancers), Lymphoma, Multiple Myeloma, Uterine (endometrial), Ovarian)
Immune System/Infections
18-0560
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
